Cargando…

SCFA Treatment Alleviates Pathological Signs of Migraine and Related Intestinal Alterations in a Mouse Model of NTG-Induced Migraine

Background: There is a growing realization that the gut–brain axis signaling is critical for maintaining the health and homeostasis of the Central Nervous System (CNS) and the intestinal environment. The role of Short-Chain Fatty Acids (SCFAs), such as Sodium Propionate (SP) and Sodium Butyrate (SB)...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanza, Marika, Filippone, Alessia, Ardizzone, Alessio, Casili, Giovanna, Paterniti, Irene, Esposito, Emanuela, Campolo, Michela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535085/
https://www.ncbi.nlm.nih.gov/pubmed/34685736
http://dx.doi.org/10.3390/cells10102756
_version_ 1784587692637421568
author Lanza, Marika
Filippone, Alessia
Ardizzone, Alessio
Casili, Giovanna
Paterniti, Irene
Esposito, Emanuela
Campolo, Michela
author_facet Lanza, Marika
Filippone, Alessia
Ardizzone, Alessio
Casili, Giovanna
Paterniti, Irene
Esposito, Emanuela
Campolo, Michela
author_sort Lanza, Marika
collection PubMed
description Background: There is a growing realization that the gut–brain axis signaling is critical for maintaining the health and homeostasis of the Central Nervous System (CNS) and the intestinal environment. The role of Short-Chain Fatty Acids (SCFAs), such as Sodium Propionate (SP) and Sodium Butyrate (SB), has been reported to counteract inflammation activation in the central and Enteric Nervous System (ENS). Methods: In this study, we evaluated the role of the SCFAs in regulating the pathophysiology of migraine and correlated dysregulations in the gut environment in a mouse model of Nitroglycerine (NTG)-induced migraine. Results: We showed that, following behavioral tests evaluating pain and photophobia, the SP and SB treatments attenuated pain attacks provoked by NTG. Moreover, treatments with both SCFAs reduced histological damage in the trigeminal nerve nucleus and decreased the expression of proinflammatory mediators. Ileum evaluation following NTG injection reported that SCFA treatments importantly restored intestinal mucosa alterations, as well as the release of neurotransmitters in the ENS. Conclusions: Taken together, these results provide evidence that SCFAs exert powerful effects, preventing inflammation through the gut–brain axis, suggesting a new insight into the potential application of SCFAs as novel supportive therapies for migraine and correlated intestinal alterations.
format Online
Article
Text
id pubmed-8535085
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85350852021-10-23 SCFA Treatment Alleviates Pathological Signs of Migraine and Related Intestinal Alterations in a Mouse Model of NTG-Induced Migraine Lanza, Marika Filippone, Alessia Ardizzone, Alessio Casili, Giovanna Paterniti, Irene Esposito, Emanuela Campolo, Michela Cells Article Background: There is a growing realization that the gut–brain axis signaling is critical for maintaining the health and homeostasis of the Central Nervous System (CNS) and the intestinal environment. The role of Short-Chain Fatty Acids (SCFAs), such as Sodium Propionate (SP) and Sodium Butyrate (SB), has been reported to counteract inflammation activation in the central and Enteric Nervous System (ENS). Methods: In this study, we evaluated the role of the SCFAs in regulating the pathophysiology of migraine and correlated dysregulations in the gut environment in a mouse model of Nitroglycerine (NTG)-induced migraine. Results: We showed that, following behavioral tests evaluating pain and photophobia, the SP and SB treatments attenuated pain attacks provoked by NTG. Moreover, treatments with both SCFAs reduced histological damage in the trigeminal nerve nucleus and decreased the expression of proinflammatory mediators. Ileum evaluation following NTG injection reported that SCFA treatments importantly restored intestinal mucosa alterations, as well as the release of neurotransmitters in the ENS. Conclusions: Taken together, these results provide evidence that SCFAs exert powerful effects, preventing inflammation through the gut–brain axis, suggesting a new insight into the potential application of SCFAs as novel supportive therapies for migraine and correlated intestinal alterations. MDPI 2021-10-14 /pmc/articles/PMC8535085/ /pubmed/34685736 http://dx.doi.org/10.3390/cells10102756 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lanza, Marika
Filippone, Alessia
Ardizzone, Alessio
Casili, Giovanna
Paterniti, Irene
Esposito, Emanuela
Campolo, Michela
SCFA Treatment Alleviates Pathological Signs of Migraine and Related Intestinal Alterations in a Mouse Model of NTG-Induced Migraine
title SCFA Treatment Alleviates Pathological Signs of Migraine and Related Intestinal Alterations in a Mouse Model of NTG-Induced Migraine
title_full SCFA Treatment Alleviates Pathological Signs of Migraine and Related Intestinal Alterations in a Mouse Model of NTG-Induced Migraine
title_fullStr SCFA Treatment Alleviates Pathological Signs of Migraine and Related Intestinal Alterations in a Mouse Model of NTG-Induced Migraine
title_full_unstemmed SCFA Treatment Alleviates Pathological Signs of Migraine and Related Intestinal Alterations in a Mouse Model of NTG-Induced Migraine
title_short SCFA Treatment Alleviates Pathological Signs of Migraine and Related Intestinal Alterations in a Mouse Model of NTG-Induced Migraine
title_sort scfa treatment alleviates pathological signs of migraine and related intestinal alterations in a mouse model of ntg-induced migraine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535085/
https://www.ncbi.nlm.nih.gov/pubmed/34685736
http://dx.doi.org/10.3390/cells10102756
work_keys_str_mv AT lanzamarika scfatreatmentalleviatespathologicalsignsofmigraineandrelatedintestinalalterationsinamousemodelofntginducedmigraine
AT filipponealessia scfatreatmentalleviatespathologicalsignsofmigraineandrelatedintestinalalterationsinamousemodelofntginducedmigraine
AT ardizzonealessio scfatreatmentalleviatespathologicalsignsofmigraineandrelatedintestinalalterationsinamousemodelofntginducedmigraine
AT casiligiovanna scfatreatmentalleviatespathologicalsignsofmigraineandrelatedintestinalalterationsinamousemodelofntginducedmigraine
AT paternitiirene scfatreatmentalleviatespathologicalsignsofmigraineandrelatedintestinalalterationsinamousemodelofntginducedmigraine
AT espositoemanuela scfatreatmentalleviatespathologicalsignsofmigraineandrelatedintestinalalterationsinamousemodelofntginducedmigraine
AT campolomichela scfatreatmentalleviatespathologicalsignsofmigraineandrelatedintestinalalterationsinamousemodelofntginducedmigraine